NCT03954652 is a NA clinical trial of WGS-Diagnostic in Rare Diseases, sponsored by University Hospital Tuebingen.

Who is sponsoring NCT03954652?

NCT03954652 is sponsored by University Hospital Tuebingen.

What drugs are being tested in NCT03954652?

Interventions in NCT03954652: WGS-Diagnostic.

What condition does NCT03954652 study?

NCT03954652 studies Rare Diseases, Genetic Predisposition.

Is NCT03954652 still recruiting?

NCT03954652 is currently completed. Last updated 18 October 2022.

Last reviewed 2022-10-18 · How we verify

NCT03954652

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - "GENOME FIRST APPROACH"

Completed NA Last updated 18 October 2022

What this trial tests

NA trial testing WGS-Diagnostic in Rare Diseases in 1,350 participants. Completed in 1 October 2022.

Timeline

1 October 2019

Primary endpoint
1 October 2022

1 October 2022

Quick facts

Lead sponsor	University Hospital Tuebingen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	1,350
Start date	1 October 2019
Primary completion	1 October 2022
Estimated completion	1 October 2022
Sites	1 location across Germany

Drugs / interventions tested

WGS-Diagnostic

Conditions studied

Rare Diseases — all drugs for Rare Diseases →
Genetic Predisposition — all drugs for Genetic Predisposition →

Sponsor

University Hospital Tuebingen

Who can join

Eligibility, any sex, with Rare Diseases or Genetic Predisposition. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The GENOME FIRST APPROACH project will enroll patients (n = 450) and their healthy parents with unclear molecular cause of the disease, suspected genetic cause of the disease and the healthy parents of those affected for trio analysis (N in total 1350).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Genomes in clinical care.
Riess O, Sturm M, Menden B, Liebmann A, et al · · 2024 · cited 18× · PMID 38485733 · DOI 10.1038/s41525-024-00402-2
Clinical trio genome sequencing facilitates the interpretation of variants in cancer predisposition genes in paediatric tumour patients.
Schroeder C, Faust U, Krauße L, Liebmann A, et al · · 2023 · cited 7× · PMID 37507557 · DOI 10.1038/s41431-023-01423-8

Verify or expand the search:

Other recruiting trials for Rare Diseases

Currently open trials in the same condition.

NCT06595940 — Genetic Analysis of Uncommon Disease Presentations in Non-US Populations · recruiting
NCT07247279 — Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia · recruiting
NCT07102966 — Genetic Study to Determine the Cause of Birth Defects in Newborns in Texas · NA · recruiting
NCT06856902 — BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe · NA · recruiting
NCT06926127 — Genomic Profiling of Genetic and Rare Diseases · NA · recruiting

Other University Hospital Tuebingen trials

Trials by the same sponsor.

NCT07378670 — DEfeating PEnile CAncer-2 · NA · recruiting
NCT07276503 — Verification of a New Predictive Delirium Score in Adults With Elective Cardiac Valve or Bypass Surgery With Perioperati · not yet recruiting
NCT07411365 — Dual-task Cognitive-motor Telerehabilitation in Persons With PD-MCI · NA · not yet recruiting
NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
NCT07378891 — Artificial-Intelligence-based Early Detection of Diabetic Retinopathy (FUNDUS AI) · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03954652 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Tuebingen
Last refreshed: 18 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03954652.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing